Lisata Therapeutics Inc. (NASDAQ: LSTA) Stock Information | RedChip
Image

ASK REDCHAT® ANYTHING ABOUT LISATA THERAPEUTICS INC.

Lisata Therapeutics Inc. (NASDAQ: LSTA)
Listen to this Section


$2.63
-0.0840 ( -2.95% ) 5.4K

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Market Data


Open $2.63
Previous Close $2.71
Volume 5.4K
Market Cap $23.00M
Day Range $2.60 - $2.75
52 Week Range $2.19 - $4.20
Shares Outstanding 8.39M
Change % -2.95%
Net Change ▼ -0.0840
Insider Ownership -0.01%
Exchange NASDAQ
Sector Healthcare
Industry Misc Health and Biotechnology Services
IPO Year 1999
Country United States

Insider Ownership Transactions

Total Amount Purchased: -222,334.00

Date Type Amount Purchased Purchaser
2024-01-12 Sale -1026.00 Mazzo David J
2024-01-11 Sale -19480.00 KLOSK STEVEN M
2024-01-11 Sale -19480.00 HENSON HEIDI
2024-01-11 Sale -19480.00 AZAB MOHAMMAD
2024-01-11 Sale -94000.00 Mazzo David J
2024-01-11 Sale -19480.00 BROWN GREGORY B
2024-01-11 Sale -19480.00 Flowers Cynthia Louise
2024-01-11 Sale -27000.00 Buck Kristen K
2023-09-05 Sale -2908.00 Buck Kristen K

Institutional Ownership

Total Market Value $ 0.00

Symbol Issuer Name Market Value ↓ Share Quantity
No records found.

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 80 Nov 12, 2024
8-k 8K-related 68 Nov 12, 2024
4 Insider transactions 1 Oct 02, 2024
4 Insider transactions 1 Oct 02, 2024
4 Insider transactions 1 Oct 02, 2024
424b5 Other 2 Aug 21, 2024
10-q Quarterly Reports 80 Aug 12, 2024
8-k 8K-related 65 Aug 12, 2024
s-8 Registration statements 5 Jul 15, 2024
8-k 8K-related 13 Jun 27, 2024

Latest News


× Before browsing our site, please accept our cookies policy